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Abstract
Genome wide association studies frequently reveal associations between disease susceptibility and polymorphisms outside
coding regions. Such associations cannot always be explained by linkage disequilibrium with changes affecting the
transcription products. This has stimulated the interest in characterising sequence variation influencing gene expression
levels, in particular in changes acting in cis. Differences in transcription between the two alleles at an autosomal locus can
be used to test the association between candidate polymorphisms and the modulation of gene expression in cis. This type
of approach requires at least one transcribed polymorphism and one candidate polymorphism. In the past five years,
different methods have been proposed to analyse such data. Here we use simulations and real data sets to compare the
power of some of these methods. The results show that when it is not possible to determine the phase between the
transcribed and potentially cis acting allele there is some advantage in using methods that estimate phased genotype and
effect on expression simultaneously. However when the phase can be determined, simple regression models seem
preferable because of their simplicity and flexibility. The simulations and the analysis of experimental data suggest that in
the majority of situations, methods that assume a lognormal distribution of the allelic expression ratios are both robust to
deviations from this assumption and more powerful than alternatives that do not make these assumptions.
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Introduction
In recent years, analysis of allelic expression has increasingly
been used to ascertain in vivo the influence of sequence variants
suspected to affect expression in cis [1–4]. Such variants modulate
expression from the same chromosome on which they are located
include, for example, changes affecting gene promoters or
sequence elements regulating message stability. This is in contrast
to factors acting in trans that affect transcription of target genes
irrespective of their genomic location and whose action is
mediated by diffusible components such as transcription factors.
Changes acting in trans affect both alleles. In individuals
heterozygous for one or more transcribed polymorphisms, the
contribution of each of the two alleles is assessed by quantifying the
relative amount of transcripts from each. Unequal expression
designated here as allelic expression imbalance (AEI, also called
allele specific expression, ASE, or differential allelic expression,
DAE), in individuals heterozygous for a putative cis acting
polymorphism is seen as evidence for cis acting effects. The
principle is depicted in Figure 1. It represents an individual
heterozygous for a cis acting polymorphism with alleles T and C;
and a transcribed polymorphism with alleles A and G. This second
polymorphism allows us to ascertain the origin of each transcript.
The figure shows that transcripts carrying the A allele are more
abundant than those carrying the allele G. This is consistent with
the T allele of the cis acting polymorphism being associated with
overexpression (compared to allele C). The rationale behind the
use of allelic expression as a tool for mapping cis acting
polymorphisms is that it should be relatively insensitive to
influences affecting both alleles such as sample degradation or
trans acting effects, compared to methods that analyse expression
from both alleles as a pool. Indeed, several recent reports have
found that allelic expression analysis can be more powerful in
detecting cis acting variants than traditional expression quantita-
tive trait locus (eQTL) analysis [1,2]. This is of particular interest
since the effects of polymorphisms may vary between tissues and
developmental stages [5,6], and assessing these effects in tissues
where availability is limited will be facilitated by using more
sensitive methods of analysis.
Allelic expression is often assessed by applying established
genotyping methods to cDNA instead of genomic DNA. In a
typical experiment DNA and RNA samples are collected from a
panel of individuals. We will use here the term sample size for the
number of individuals in the panel. The DNA is genotyped for a
set of markers that includes at least one marker that is located
within the transcript of interest. For individuals heterozygous for
the transcribed polymorphism, the RNA, usually after reverse
transcription, is used to quantify the relative amounts of transcripts
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28636
originating from each of the two alleles. The outcomes of such an
experiment are the genotype frequencies in the panel of
individuals and allelic expression ratios for the individuals that
are heterozygous for the transcribed marker. Figure 2 shows an
example for such results. Represented are the observed allelic
expression ratios measured for a transcribed single nucleotide
polymorphism (SNP) at the 39 end of the MMP1 gene grouped
according to the genotype for a polymorphism in the promoter
region the gene (Data taken from [7]). The latter is an insertion/
deletion polymorphism with alleles G and GG. The data were
collected to assess whether the polymorphism in the promoter
region is associated with changes in expression in lung tissue in vivo
[8]. The methods employed to quantify the relative contribution of
transcripts from each allele include: restriction fragment analysis
[8], DHPLC [9], primer extension using chain terminators and
quantification using capillary electrophoresis [5] or mass spectros-
copy [10], real time PCR [11], ligations assays [12,13], or
differential hybridisation to oligonucleotide arrays [3,4,14–17].
Establishing whether an allele is preferentially transcribed requires
controls where both alleles are represented in defined proportions.
Often, genomic DNA is used as an equimolar control. More
recently, transcriptome sequencing has also been used to assess
allelic expression levels [18,19].
Allelic expression can be treated as a qualitative trait, describing
the presence or absence of imbalance and perhaps which allele is
overexpressed. It can also be considered as a quantitative trait. We
will use here the term allelic expression ratio (AER) for the ratio of
the signal intensity emanating from one allele, as defined by the
transcribed polymorphism, divided by that from the other (e.g.
[1,7,20]). Alternatives include using the sum of the signal
intensities from both alleles in the denominator (e.g. [21]), or
consistently using the ratio of signal from the highest expressed
allele divided by that from the lowest expressed one (e.g. [22]).
Mapping using allelic expression can be thought of as assessing
whether the pattern of imbalance observed across a series of
individuals is consistent with a cis acting effect for each
polymorphism from a set of SNPs. Here we will concentrate on
the simplest case where only one candidate polymorphism is tested
and only one transcribed polymorphism is used. For an individual
that is heterozygous at both the transcribed and the cis acting sites,
the transcribed allele that is overexpressed will be the one that is
on the same chromosome as the as the cis acting allele causing
overexpression. The phase between alleles at the two sites can vary
from individual to individual. Therefore assessing the effect of a
putative cis acting polymorphism may require determining the
phase of the alleles at the transcribed and cis acting sites. This is
particularly simple when the polymorphism of interest is the
transcribed polymorphism itself, resulting in the systematic
overexpression of the same allele in heterozygotes, or when both
polymorphisms are in complete linkage disequilibrium, where little
imbalance will be expected for those homozygous at the cis acting
site, while those that are heterozygous should show systematic
overexpression of the same transcribed allele [5]. In general, when
there is less than complete disequilibrium or when the extent of
disequilibrium is unknown, there are two possible approaches. The
first separates phase estimation from assessing the effect upon
transcription. Phase estimation can be done using population data
or observing co-segregation of alleles within families. One of the
advantages of such an approach is the availability of a plethora of
software packages for this purpose (reviewed e.g. in [23,24]). Once
the phase has been taken into account the evidence for the cis-
acting effect can then be assessed. This analysis can be carried out
either using the most likely phased genotype [18], or the estimated
distribution of possible phased genotypes [1] for each individual. A
second approach is to estimate phase and the cis-acting effect
simultaneously ([2,7,25]).
For one transcribed and one cis acting polymorphism the
principles underlying different approaches for testing can be
illustrated using Figure 3. These figures include only individuals
Figure 1. Diagrammatic representation of the effect of a cis
acting polymorphism upon allelic expression. Depicted is the
situation for an individual who is heterozygous for a cis acting
polymorphism with alleles A and C and is also heterozygous for a
polymorphism within the affected transcript.
doi:10.1371/journal.pone.0028636.g001
Figure 2. Observed allelic expression ratiosmeasured at rs5854,
a transcribed polymorphism at the 39 end of the MMP1 gene
grouped according to the genotype for rs11292517, a poly-
morphism in the promoter region of the gene.
doi:10.1371/journal.pone.0028636.g002
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who are heterozygous for the transcribed SNP, since AER cannot
be measured in homozygotes (although the genotype for the
putative cis acting SNP can vary). The distinct approaches arise
due to the extent of linkage disequilibrium present. Panel A
represents the relationship between the genotype and allelic
expression ratios in the general situation. Panels B to D illustrate
the reasoning underlying different tests that have been used. In the
simplest case where both polymorphisms are in perfect disequi-
librium or the cis acting and the transcribed polymorphism are one
and the same, testing the effect is consistent with assessing a
systematic deviation from balanced expression in one direction
(Panel B). Panel C depicts the situation where there is complete
disequilibrium. Here the effect of the putative functional
polymorphism should result in the systematic overexpression of
one and the same transcribed allele in heterozygotes that is not
observed among homozygotes. This suggests using a test to assess
differences in allelic expression ratios from both groups (e.g. [26]).
The situation when the phase is known or can be inferred so that
any remaining uncertainty can be neglected is depicted in Panel D.
In this case the effect of the putative cis acting polymorphism can
be assessed by testing the correlation between genotype and ratio,
where the genotypes are coded so that the value assigned to
homozygotes at the cis acting locus is exactly midway between
those assigned to the heterozygotes (e.g. [4]).
Nonparametric tests are preferred when there are concerns
about sample distribution properties. Their use has been limited to
the scenarios presented in Panels B to C, where linkage
disequilibrium (LD) is strong (D9=1), or Panel D when phase
can be confidently inferred.
In order to test the power we simulate the allelic expression. The
simplest assumption is to presume that expression from each allele
is lognormally distributed. However in practice the patterns
observed are more complicated. Several elements contribute to
this. Detailed studies routinely uncover that transcription is
Figure 3. A visualisation of different approaches for testing an association between allelic expression and a biallelic polymorphism.
The distribution of allelic expression ratios across a population is represented. We consider here two polymorphisms: a transcribed one, with alleles m
and M, used to measure allelic expression; and a cis acting one with alleles c and C. Each elongated diamond represents the mean and the spread of
the AEI measurements by specific genotypes. A) The general situation. B) Perfect disequilibrium (D9= 1, R2 = 1) between the cis acting and the
transcribed polymorphism, only two distinct haplotypes exist. C) Complete disequilibrium (D9=1, R2,1), only three distinct haplotypes exist. D)
Situation when the phase between alleles at both sites is known.
doi:10.1371/journal.pone.0028636.g003
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influenced by more than one polymorphism [1,27]. In addition we
should consider that expression itself is a result of cis and trans
acting factors, therefore although a polymorphism may act in cis in
a certain context this effect is mediated by trans acting factors that
may themselves by the subject of variation caused either by
environmental [5,6,28,29] or genetic factors [30]. A related issue is
the presence of outliers. This is apparent from the analysis in
disease predisposing loci. For example in MLH1 or BRCA1, two
genes involved in cancer predisposition, mutations causing
nonsense mediated decay lead to a substantial degree of imbalance
that overlays the variation due to common polymorphisms. The
degree of imbalance in mutation carriers is up to fivefold larger
than that observed in samples without mutations (e.g. [25,31]).
Such observations suggest that AEI can be used to identify likely
mutation carriers [25] or to assess whether a particular gene is
involved in disease predisposition [15]. They also show that rare
alleles with a substantial effect on expression can obscure the effect
of common alleles.
Here we examine several different but commonly used
approaches to the analysis of allelic expression. We focus on the
power of different methods to identify sites associated with
expression differences in cis. We concentrate on the association
between allelic expression and particular biallelic polymorphisms
and we compare the power using simulated and published data
sets.
Methods
This section has of two parts. In the first part we present the
different statistical methods to be compared and in the second we
describe and discuss the models used in the simulations. The
simulations are used to test the power to detect the effect of a single
polymorphism on the AER measured using a single transcribed
polymorphism. We consider only biallellic polymorphisms. A
significance level threshold of 0.05 is assumed throughout.
Statistical Tests: We limit our consideration to previously
published approaches or existing methods. These tests assume
that the data consist of a set of individuals who have been typed for
a putative cis acting polymorphism and transcribed marker, and
that allelic expression has been measured in those individuals that
are heterozygous for the transcribed marker. We use the term
sample size to describe the number of individuals genotyped,
irrespective of the transcribed marker genotype. The tests can be
divided in two groups. The first group relies on a model of the
process generating allelic expression. The second group consists of
simple statistical tests appropriate for one or more of the instances
depicted in Figure 3.
We use the following notation: For the i-th individual we
designate with Ti the genotyping results for both loci and with Ii
the log of the allelic expression ratio. The first set of tests (four in
total) are likelihood ratio tests that rely on the assumption that the
allelic expression ratios are lognormally distributed with a
genotype dependent mean mG and a genotype independent
variance s2. We describe the influence of the genotype and on
mG as mG~mhG , where m represents the effect of the cis acting
polymorphism and hG the phase between alleles as both sites, i.e. if
we designate with M and m the alleles at the transcribed site and
with C and c the alleles of the cis acting polymorphism then
hG~
1 for G~MC=mc
{1 G~Mc=mC
0 otherwise
8><
>:
:
The tests assuming an underlying model differ in the likelihood
that is maximised. Test LRT.j jointly maximises the parameters
describing both expression and haplotype frequencies. The
likelihood L can be decomposed in two components: L~LnLe.
The first is determined by the genotypes of the samples where no
allelic expression was measured (this includes the individuals who
are homozygous and hence their genotypes for the transcribed
marker are MM or mm): Ln~P
j
P Tið Þ~P
j
X
g
P Tj jg
 
P gð Þ,
where P Tið Þ is the probability of the genotyping results, P gð Þ the
probability of the genotype g given the haplotype frequencies, the
index j runs through all individuals in the sample for which no
AER was measured and g through all phased genotypes defined by
the two polymorphisms. The second component describes the
contribution of samples for which AER was measured
Le~P
i
f Ii,Tið Þ~P
i
X
g
f Iijgð ÞP Tijgð ÞP gð Þ, where P Tijgð Þ,
f Iijgð Þ, where the index i runs through all individuals. This test
(LRT.j) represents an extension of the procedure described by
Teare et al. [7] and was used in [25].
The second test we consider is LRT.p which maximises the
probability of the log expression ratio given the genotyping results
:L~P
i
f IijTið Þ~P
i
X
g
f Iijgð ÞP gjTið Þ. Such a procedure was
used in [1]. This method differs from LRT.j in that the haplotype
frequencies are inferred (or ‘prephased’) from the genotyping
results through a preliminary step. For the results presented here
this was done here using an Expectation Maximisation (EM)
algorithm.
Test LRT.b uses instead of the distribution of haplotypes only
the most likely haplotype. Thus the likelihood of interest can be
described as L~P
i
f IijGi
 
, where Gi designates the most likely
phased genotype for individual i. This specific application is
equivalent to fitting a simple linear regression.
Test LRT.k uses the true or known genotypes instead of the most
likely ones. This final LRT test is examined as a gold standard
comparison, but in practice the true haplotypes for double
heterozygotes are frequently not known.
The second set of procedures we include, rely on some widely
used tests, whose application to the analysis of allelic expression is
motivated by the considerations discussed in relation to Figure 3.
The first approach we investigate consists of using a sign test (S) to
assess whether there is a systematic overexpression of one of the
transcribed alleles. The sign test uses only the data observed in the
single group of individuals who are heterozygous at the putative cis
acting SNP. The second approach uses the Mann-Whitney or
Wilcoxon test (W) to assess whether there is a difference in AER
between individuals that are homozygous or heterozygous at the
cis acting site. In perfect LD (only the double heterozygote group is
observed) the test is assumed to fail and a nonsignificant result is
returned. These two tests do not assume lognormality of the ratios.
A third procedure investigates whether there is a correlation
between AER and the phased genotype (where MC/mc is coded
as 21; MC/mC or Mc/mc as 0; and Mc/mC as 1). This requires
assigning one phased genotype to each individual. To apply the
test in the case of haplotype phase uncertainty (C) the
heterozygous individuals are assigned the most likely phase,
resulting in only one heterozygote group. We compare the results
using the same test but using the true or known simulated
genotypes (C.k).
A fourth possibility we investigate is to compare the variance of
AER between homozygous and heterozygous at the cis acting site
using an F-test (V). This test would appear most suitable under
linkage equilibrium (see Figure 1 A).
Allelic Expression Mapping
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28636
While it is unlikely that the haplotype phase would be known,
we show the results of applying some methods to known phase
data to see the loss in power due to lack of information.
A summary and overview of the tests used is presented in
Table 1.
Simulations: The data were simulated under four basic models.
This allowed us to explore the effects of different parameter values
as well as different assumptions concerning the processes
modulating allelic expression. In all our simulations we assume
that the variance of the expression from one chromosome is
independent of its genotype and from expression levels and that
the effects of different polymorphisms combine in a multiplicative
manner, i.e. for a set of K cis acting polymorphisms with effects bk
(k~1,:::,K ) the expected log of the allelic expression ratio in a
sample is
XK
k~1
bkhk where hk describes the phase between the
alleles at the k-th cis acting polymorphism with respect to the
transcribed marker allele in this sample.
The first set of simulations assumes that allelic expression is
influenced only by a single biallelic site and that for each allele
expression can be described by a lognormal distribution. The model
can be described by five parameters: three haplotype frequencies,
the expected log ratio of expression from the one of the cis acting
alleles divided by that from the other allele, and the variance.
The second set of simulations considers the commonly
encountered situation when one of the transcribed alleles is
overexpressed and investigates the power to detect the effect of a
second cis acting polymorphism. Such consistent overexpression of
one of the transcribed alleles is often reported (e.g. [20]). This can
be a consequence of cis acting polymorphisms in perfect
disequilibrium with the transcribed marker or can reflect problems
with the normalisation to equimolar controls. This model includes
a parameter b0 which describes the mean overexpresssion of one
of the transcribed alleles relative to that of the other. In our model
this corresponds to the expected ratio for the homozygotes at the
cis-acting candidate.
Table 1. Summary of tests used.
Test Motivationa Advantages Disadvantages Notes
LRT (Likelihood
Ratio Tests)
General situation Easy to expand (e.g.
several cis acting sites).
Assumption of
Log normality.
Assume that expression
from one allele is drawn from
a lognormal distribution
LRT.j (joint) Requires
specialised software
Enables joint estimation
of phase and effect.
LRT.p (prephased) Compared to LRT.j
reduced power in the
absence of
disequilibrium
Two step procedure: In the
first step the phased genotype
probabilities are estimated and in
the second the effect is assessed.
LRT.b (most likely
genotype , ‘‘best’’)
Simple calculation Lack of power
when phase
uncertain
As LRT.p but uses the most likely
(best) phased genotype for each
individual For R2,1 corresponds
to regression of the log AER
onto the most likely genotype.
LRT.k (known
genotype)
As LRT.b but uses true simulated
genotype. Represents the outcome
of the LRT tests once phase
uncertainty has been eliminated.
S (Sign) Perfect disequilibrium
(R2 = 1)
No assumption
on distribution
Diminishing power
when SNPs tend to
equilibrium
Tests systematic overexpression
of one of the alleles. We use
here the Sign test.
V (Variance) Linkage equilibrium
(|D9| = 0,R2 = 0)
Does not require
estimating phase
Diminishing power
with increasing
disequilibrium.
Assumes
lognormalityb
Tests whether the spread of AER
is larger among heterozygous at
the cis acting locus than among
homozygous. We use here an
F-test for the comparison
C (Correlation) |D9|,1, R2,1. Insensitive to
transcribed
marker effect
Lack of power when
phase uncertain.
Assumes
lognormalityb
Requires at least two distinct
genotypes to be observed at the
cis acting site among transcribed
marker heterozygotes. Assumes
that the phase can be inferred in
double heterozygotes, so we use
here the most likely genotype.
C.k (Correlation ,
known genotype)
|D9|,1, R2,1. Represents the outcome of the
test above once phase
uncertainty has been eliminated.
W (Wilcoxon) Complete disequilibrium
(|D9| = 1,R2,1)
No assumption
on distribution
Assumes that all
double heterozygotes
have the same
phased genotype
Tests whether there is a
difference in AER between
heterozygotes and homozygotes
for the cis acting polymorphism.
We use here the Wilcoxon test.
a: Pattern of disequilibrium, as represented in Figure 3, for which the test is most appropriate.
b: Assumes that given the genotype AERs follow a log normal distribution.
doi:10.1371/journal.pone.0028636.t001
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The third set of simulations allows expression to be determined
by several sites. We assume that we are investigating the site with
the largest effect, that expression is influenced by a number of sites,
that the effect size follows an exponential distribution, that all
effects are mediated by biallelic polymorphisms and that the
additional sites are in linkage equilibrium with both the
transcribed and our test polymorphism. We further assume that
the allele frequencies at all of the cis acting loci are equal to 0.5 and
that there is no effect from the transcribed polymorphism. We
expand the first model to include the n additional cis acting sites.
We first simulate the phased genotypes of K individuals for n+2
biallelic loci. The minor allele frequencies for the first two markers
are pM and pC and for the remaining ones 0.5. The n+2 markers
are all in linkage equilibrium. The algorithmic form of the
simulations is as follows: we sample n+1 values, m1,:::,mnz1, from
an exponential distribution with a rate of 0.1. These values are
then divided by that with the largest value mm and multiplied by b,
i.e. ci~mib=mm, to ensure that the largest effect is b, this effect is
attributed to the candidate cis acting locus. We then simulate for
each individual the log ratio I*N Q,sð Þ, where the mean Q is
dependent upon the genotype: Q~bhGz
Xnz1
l~2
clhl , hG charac-
terises the phase between alleles at the transcribed and the main cis
acting site and hl the phase between the transcribed and l-th cis
acting marker given the genotype of the individual.
A fourth set of simulations considers the effects of outliers. We
explore here the situation that arises when the AER of some
individuals appears to be drawn from a distribution different from
the one described by the simple model used for the first set of
simulations. We assume that this is caused by the presence of
certain alleles which we call outliers. Irrespective of the genotype
at the cis acting site the logarithm of the allelic expression ratio for
an individual that is heterozygous for the transcribed marker and
carries one outlier allele is normally distributed with a mean
bouthout and a variance s
2, where hout describes the phase between
outlier allele and transcribed marker. In the case when the both
alleles are outliers with respect to expression the mean log AER
was 1. This requires two additional parameters: one describing the
mean effect of the outlier bout and a second describing the
frequency of outlier alleles pout.
In the final simulation scenario we assume that the log of the
allelic expression is not normally distributed but can be described
by a heavy tailed distribution; we use here a t-distribution with two
degrees of freedom.
Published data: We finally demonstrate the power of the various
methods in real data situations by using two previously published
data sets (Table 2). In these two examples there is experimental
evidence for the cis acting effect of the nontranscribed SNPs. The
two datasets used in this study have been previously published and
details including recruitment, sample collection and ethical
approval can be found in the original publications [8,25]. The
first set consists of data from individuals typed for a transcribed
polymorphism in the 39 untranslated region of the matrix
metalloproteinase I gene (MMP1), that were also typed for a
polymorphism in the promoter [7,8]). Reporter assays have shown
that this polymorphism can modify transcription in vitro [32]. The
individuals in the second set were assessed for a transcribed
polymorphism in the MLH1(mutL homolog 1) gene [25]. The
samples were also genotyped for a marker in the 59 region of the
gene, that has been recently been shown to influence transcription
in vitro [33]. The influence of sample size and analysis method on
power was assessed by sampling from the observed datasets with
replacement.
Results
The results are summarised and presented in five figures. Each
investigates the power of the different tests when conditions such as
sample size, extent of LD or allele frequency are permitted to vary.
The first four figures use simulated data. First we assess the power
of the different tests when AER simply follows a log normal
distribution (Figure 4), then we investigate the case when one
transcribed allele is consistently overexpressed and we wish to asses
an independent effect of the cis acting polymorphism (Figure 5).
The situation when there are additional sites affecting expression is
investigated in Figure 6. Figure 7 explores deviations from the
lognormal distribution. In the final figure (Figure 8) we use
previously published experimental data to assess the impact of
sample size.
Figure 4 explores the effects of varying parameter values using
the simplest simulation model, i.e. one cis acting polymorphism
and a lognormal distribution for the allelic expression ratios. In
panel A the transcribed and cis acting polymorphisms are in
linkage equilibrium (D9=0). The effect of sample size on the
power to detect an association with the seven different methods
can be seen. The joint phase and effect estimation (LRT.j)
performs better than methods where the haplotypes are estimated
first and the effect assessed in a separate step. However, its
performance is strongly affected by the extent of disequilibrium
Table 2. Experimental data sets.
Data set name MMP1 MLH1
References [7,8] [25]
Genotyped Individuals 107 257
Transcribed SNP rs5854 rs1799977
Cis acting SNP rs11292517a rs1800734b
AER
Individuals analysed 38 74
Method RFLP and gel densitometry MALDI-TOF
Comments Samples affected by non-sense
mediated decay have been excluded
a: [32].
b: [33].
doi:10.1371/journal.pone.0028636.t002
Allelic Expression Mapping
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between both markers. Panel B shows for a sample size of 100, that
although there is a difference between both types of methods
(LRT.j and LRT.p) the advantage diminishes quickly with
increasing disequilibrium. It should also be noted that the most
likely phase test (LRT.b) achieves a comparable power to LRT.j
for modest disequilibrium (D9=0.5). The variance test works very
well when D9=0 however as D9 increases this test only reduces in
power whereas all the other tests improve.
Changes in effect size are explored in panels C (for D9=0) and
D (D9=1). Where there is no effect (i.e. b=0) the type I error
seems adequately controlled. Under linkage equilibrium the LRT.j
is slightly more powerful than LRT.p. While the test using
Pearson’s correlation coefficient (test C) works very well when
phase is known, the test is ineffective when haplotype uncertainty
exists. The effects of changes in the allele frequency for the
transcribed polymorphism are explored in panels E and F, and of
the putative cis acting in panel G and H. The power increases with
the proportion of heterozygotes for the transcribed markers that
are also heterozygotes for the cis acting variant. Therefore in the
absence of disequilibrium (D9=0) power increases with heterozy-
gosity (panels E and G), while for D9=1 a maximum is achieved in
the presence of matching allele frequencies for the model based
tests (perfect disequilibrium, R2= 1, panels F and H). In panels F
and H we see the drop in power of the two tests C.k and W as the
system approaches perfect disequilibrium, reflecting the fact that
when there is perfect disequilibrium all heterozygotes have the
same genotype.
Figure 5 considers the case when there is an effect on
transcription associated with the transcribed polymorphism itself.
The methods tested assume either that we are unaware of an effect
associated with the transcribed polymorphism and therefore use
tests that do not explicitly consider such an effect (LRT.p, LRT.j,
LRT.k. LRT.b, W,S,C, C.k and V) or that we are aware and
employ tests that allow for the effect (LRT.p.m0, LRT.j.m0,
LRT.k.m0 and LRT.b.m0). The lines depicted in grey present
analyses in which the type I error rate is not adequately controlled.
The sign test S uses only the AER observed on heterozygotes so
this test will be affected by the transcribed SNP effect. If analysis is
conducted using the LRT approach but the b0 parameter is
neglected then these methods are compromised. Therefore we
used a set of tests (LRT.p.m0, LRT.j.m0 , LRT.k.m0 and LRT.b.m0),
that allow for an effect of the transcribed polymorphism itself.
Here the expected log AER is described as mG~mhGzm0, where
m0 represents the effect of the transcribed polymorphism. The
LRT.j and LRT.p both perform well and much better than the
LRT.b and the correlation test (C).
Figure 6 presents the results for the scenario of multiple cis
acting loci, though there is now no effect of the transcribed marker
itself. The simulations constrain the effect of the candidate SNP to
be the strongest effect. As should be anticipated power reduces
Figure 4. Power comparisons when data are simulated assuming a log normal distribution for the allelic expression ratios. For all
simulations: s~1. Panel A: Effect of sample size assuming transcribed and cis acting polymorphism are in linkage equilibrium (Simulation parameters:
D0~0,b~1,pM~0:5 and pC~0:25 ). Panel B: The influence of the extent of disequilibrium (Simulation parameters: N~100,b~1,pM~0:5,pC~0:25);
Panels C and D: The influence of effect size (Panel C for D0~0 and panel D for D0~1 other simulation parameters N~100,pM~0:5,pC~0:25). Panels
E and F: The influence of allele frequency for the transcribed polymorphism (Panel E for D0~0 and panel F for D0~1, othersimulation parameters:
N~100,b~1,pC~0:25). Panels G and H: The influence of allele frequency for the cis acting variant (Panel G for D
0~0 and Panel H for D0~1,other
parameters: N~100,b~1,pM~0:25).
doi:10.1371/journal.pone.0028636.g004
Figure 5. Power comparisons when the simulated model allows for one transcribed marker allele to be consistently over-
expressed. Simulation parameters: b0~1,pM~0:5,pC~0:25,D
0~0,s~1,N~100. Analysis in greyscale is conducted using (misspecified) methods
that do not allow for an allele specific expression effect from the transcribed polymorphism (Panel A: b~0, i.e. no effect from the cis acting
polymorphism, and panel B: b~1). Panels C and D: Analysis conducted using models that do allow for an effect from the transcribed polymorphism
(Panel C: b~0 and panel D: b~1).
doi:10.1371/journal.pone.0028636.g005
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with increasing additional causative loci. This figure assumes that
D9=0.
Figure 7 explores the effects when the AER distribution deviates
from a simple lognormal distribution. Panel A presents the effects
of outliers. It shows that with increasing outlier frequency the
power is quickly lost. As expected, tests relying on a nonparametric
method to assess the influence of the cis acting polymorphisms are
affected to a lesser degree. With increasing outlier frequency the
performance of the LRT.p and that of the LRT.j method becomes
similar. The presence of outliers does not affect the ability to
determine haplotype frequencies in the former. The power of the
variance test appears to be higher than the LRT methods.
However, this is accompanied by an inflated type I error as can be
seen in panel B when the true effect size is zero. Panels C and D
show that when the log of the expression of each allele follows a t-
distribution with 2 degrees of freedom, there is a substantial loss of
power in particular for the model based methods where the phase
needs to be estimated.
Figure 8 shows the analysis of real data using two previously
published data sets (see Table 2 for details). In both cases there is
experimental evidence for the cis acting effect of the nontran-
scribed SNPs. The Figure explores the effect of varying sample
size. These two examples differ in two aspects. The first is that in
MMP1 (panel A) the cis acting and transcribed markers are close to
linkage equilibrium (D9=0.05, R2= 0.00) while in MLH1 (panel
B) they are in strong disequilibrium (D9=0.99, R2= 0.09).
Therefore we see differences in the power attained by the LRT.j,
LRT.p and LRT.b tests for MMP1 (panel A), while for MLH1 the
curves for these same tests are indistinguishable. The second
difference is that while there is no evidence for a transcribed
marker associated effect for MMP1 [7], there is systematic
overexpression of one of the transcribed alleles for MLH1 [25].
This effect is such that for double heterozygotes the allele
associated with overexpression at the cis acting polymorphism is
predominantly occurring in phase with the underexpressed
transcribed marker allele. So those tests that do not allow for a
b0 parameter will perform very poorly in this situation.
Discussion
The results demonstrate that phase uncertainty is the main
factor determining the power of the tests. However, closer
inspection of the Figures shows that this effect depends on the
allele frequencies at both sites. In the absence of disequilibrium,
i.e. when the two loci are not associated (R2 =D9=0), power
increases with increasing heterozygosity at both the transcribed
and the cis-acting sites (Figure 4, panels E and G). When. there is
no phase uncertainty in double heterozygotes, i.e. in the case of
complete LD, the power of the likelihood ratio tests and that of the
procedure based on the sign test, peak when both markers have
the same minor allele frequency, i.e. are in perfect disequilibrium
(R2= 1).
One important consequence of the influence of extent of
disequilibrium on power is that the effects of polymorphisms that
are physically closer to the transcribed marker will be easier to
detect than those of more distant markers, since disequilibrium is
expected to be weaker for the latter. Perfect disequilibrium
between transcribed and cis-acting polymorphism is equivalent to
the situation when there is an effect on transcription associated
with the transcribed polymorphism itself. However technical
artefacts such as problems with normalisation to equimolar
controls can also lead to assigning an effect to the transcribed
polymorphism.
We explored the situation where the transcribed polymorphism
influences transcription and we wish to assess an additional effect
associated with a second polymorphism. In this case, likelihood
ratio tests that do not include a baseline term (m0), have an inflated
type I error, wrongly attributing an effect where there is none.
This can be circumvented by using a test that allows for an effect
associated with the transcribed polymorphism. However the
Figure 6. Additional sites affecting the expression in cis. The graph represents the influence of the number of sites upon the power to detect
the SNP with the largest effect. All polymorphisms are assumed to be in linkage disequilibrium. Simulation parameters:
b~1,pM~0:5,pC~0:25,D
0~0,s~1,N~100.
doi:10.1371/journal.pone.0028636.g006
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Figure 7. Deviation from a simple log normal distribution (Simulation parameters pM~0:5,pC~0:25,D
0~0). Panels A and B show the
effects of outliers (bout~4,s~1). In panel A b~1 and in Panel B the outlier frequency, pout, is 0.03: Panels C and D present the situation when the log
of the expression of each allele follows a t-distribution with 2 degrees of freedom (C for D0~0 and D for D0~1).
doi:10.1371/journal.pone.0028636.g007
Figure 8. Effect of sample size in experimental data. We examine here the power to detect the cis acting effect of polymorphisms known to
affect transcription for MMP1 (panel A) and MLH1 (panel B).
doi:10.1371/journal.pone.0028636.g008
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evidence for the second effect becomes difficult to obtain when the
polymorphisms are closely associated.
The presence of outliers quickly degrades the ability to detect cis
acting sites. Since outliers distort the distribution of allelic
expression ratios, it is not surprising to observe that a
nonparametric method such as that relying on the Wilcoxon test,
is less affected. With increasing outlier frequency the performance
of the LRT.p and that of the LRT.j method become similar. This
is consistent with the fact that the presence of outliers does not
affect the ability to determine haplotype frequencies in the former,
while a misspecified model will impair estimation of haplotype
frequencies in the latter. However, the performance of the joint
estimation method does not drop below that of the method where
allele frequencies are estimated without using expression informa-
tion. Similar observations can be made when there are several cis
acting loci and where the distribution of expression is heavy tailed.
Also in these cases the allelic expression ratios given the genotype
at the cis acting and transcribed polymorphism do not follow a
lognormal distribution.
Throughout our simulations the test relying on joint maximisa-
tion of effect and haplotype frequencies is more powerful than the
test where the genotypes are estimated separately in a first step and
this is in turn more powerful than the a test were only the most
likely phase is used. This difference is substantial for the MMP1
data where for a sample size of 105 the first test has 85% power,
while the second 70% and the third 65% (Figure 8 panel A).
However the difference between the first two methods quickly
disappears with increasing disequilibrium. There is no discernable
advantage of any of the three methods for the MLH1 data. Joint
determination of phase and effect is more cumbersome than using
the predetermined haplotype frequencies, a task for which a wide
range of tools has been developed over the past fifteen years.
Indeed, a dense enough panel of typed markers may eliminate
most of the haplotype uncertainty, leading to situations where
testing can be done using linear regression (see Figure 3 panel D).
This opens the way for using standard statistical packages to assess
more complex models including several cis acting polymorphisms
and other co-variates. In our simulations and analysis the model
LRT.b is equivalent to fitting simple linear regression.
Another conclusion from our data is that for the range of
situations studied the advantage gained by using tests that dispense
from the lognormality assumption is at best slight and led, in the
majority of the simulations scenarios and in the real data sets used,
to a substantial loss of power in the ability to detect experimentally
supported polymorphisms acting in cis. The variance test that
groups the homozygotes and heterozygotes together is a powerful
test when linkage equilibrium exists, though power reduces as
disequilibrium increases. However, this test gives an inflated type I
error in the presence of outliers and extreme values.
In summary our investigation shows that when it is not possible
to determine the phase between the transcribed and potentially cis
acting allele there is generally some advantage in using methods
that estimate genotype and effect on expression simultaneously.
However when the phase can be determined, simple regression
models seem preferable. The scenarios explored here by
simulation and through experimental data show that methods
assuming lognormal distributions are the most powerful and are
generally robust with respect to presence of outliers and other
deviations from lognormality.
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